Rekombinanter Aflibercept Biosimilar Antikörper

Produktnummer ABIN7795087

Der Maus Monoklonal anti-Aflibercept Biosimilar Antikörper (ABIN7795087) detektiert spezifisch Aflibercept Biosimilar in FACS und in vivo. Dieser Antikörper reagiert spezifisch mit Proben aus Human.

Kurzübersicht für Rekombinanter Aflibercept Biosimilar Antikörper (ABIN7795087)

Target: Aflibercept Biosimilar

Antikörpertyp: Recombinant Antibody

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Applikation: Flow Cytometry (FACS), In vivo Studies (in vivo)

Güteklasse: Research Grade

Produktdetails

Expressionssystem: Mammalian cells

Verwendungszweck: Aflibercept Biosimilar

Produktmerkmale: What is research grade Aflibercept biosimilar? Research grade Aflibercept biosimilar has the same amino acid sequence as Aflibercept (trade name Eylea), a recombinant protein composed of the binding domains of two human vascular endothelial growth factor (VEGF) receptors fused with the Fc region of human immunoglobulin gamma 1 (IgG1). It inhibits vascular endothelial growth factor (VEGF), and is used in the treatment of macular edema following Central Retinal Vein Occlusion (CRVO) and neovascular Age-Related Macular Degeneration (AMD). Aflibercept is a dimeric glycoprotein with a molecular weight of 96.9 kilo Daltons ( kDa). Glycosylation adds its molecular weight to 115 kDa in total. Ziv-aflibercept (trade name Zaltrap) was developed as an injection for treatment of metastatic colorectal cancer.

Aufreinigung: Protein A or G affinity column

Reinheit: >95 % by reducing SDS-PAGE

Endotoxin-Niveau: < 1 EU per 1 mg of the protein by the LAL method

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: > 3 mg/mL

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.

Antigendetails

Target: Aflibercept Biosimilar

Substanzklasse: Biosimilar